QuintessenceLabs to Develop Quantum Key Distribution Technology under Agreement

QuintessenceLabs, a leader in quantum communications technology for networking, communications, national security and defence, has announced a partnership with Lockheed Martin Corporation for the development of its Quantum Key Distribution technology towards applications in Australian and US markets. The relationship confirms an announcement made during National E-Security Awareness Week at an address to The National Press Club of Australia in Canberra.

QuintessenceLabs’ second generation QKD technology integrates seamlessly with preexisting communications infrastructure providing one-time pad encryption in real-time. Products incorporating QuintessenceLabs’ bright laser technology can achieve high speed, untappable communications at a fraction of the cost of competing technologies.

Commenting on the announcement, QuintessenceLabs Chairperson, Peter Shergold, said “We are delighted to be entering into partnership with Lockheed Martin. Lockheed Martin is a global technology leader which has identified national security as a key strategic priority. Following an evaluation of QuintessenceLabs’ technology, Lockheed Martin decided to enter into this relationship to develop leading edge information security solutions”.

“We are pleased to have this relationship with QuintessenceLabs”, said Paul Johnson, CEO of Lockheed Martin Australia, “Global security is a major focus for Lockheed Martin and we are delighted to be working with QuintessenceLabs, a company at the forefront of QKD technology that has important information security applications. We believe that QKD technology has great promise worldwide and look forward to a continued partnership”.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.